RCM Technologies, Inc. Announces Third Quarter 2026 Results

RCM Technologies posts steady revenue and profit growth with strong non-GAAP improvements.

What the company is saying

RCM Technologies, Inc. (NASDAQ:RCMT) is presenting a narrative of consistent financial growth, emphasizing both GAAP and non-GAAP improvements for the thirteen and thirty-nine weeks ended October 3, 2026. The company highlights a 4.4% year-over-year revenue increase to $73.4 million for the quarter and a 7.4% year-to-date rise to $250.3 million. Gross profit and net income also improved, with quarterly GAAP net income at $2.7 million ($0.37 per diluted share) and year-to-date GAAP net income at $11.5 million ($1.56 per diluted share). The announcement places particular focus on non-GAAP metrics, noting a 14.2% increase in adjusted EBITDA to $6.3 million for the quarter and a 26.2% jump in adjusted net income per diluted share to $0.53. Segment results are broken out, showing Specialty Healthcare as the largest contributor, and consolidated gross margin remains stable. The tone is factual and confident, with no forward-looking statements or speculative language.

What the data suggests

The disclosed figures show modest but broad-based financial improvement. Quarterly revenue rose from $70.3 million to $73.4 million, and gross profit increased from $19.4 million to $19.9 million. GAAP net income for the quarter grew from $2.3 million to $2.7 million, and diluted EPS increased from $0.30 to $0.37. Year-to-date, revenue climbed from $232.9 million to $250.3 million, gross profit from $63.7 million to $66.0 million, and GAAP net income from $10.2 million to $11.5 million. Non-GAAP adjusted EBITDA and adjusted net income per diluted share outpaced GAAP growth, with adjusted EBITDA up 14.2% for the quarter and 11.0% year-to-date, and adjusted net income per diluted share up 26.2% for the quarter and 16.2% year-to-date. Segment data shows Specialty Healthcare leading in revenue, while Life Sciences, Data and Solutions maintains the highest gross margin. The company’s cash position is low at $1.9 million, and net cash used in operating activities was $3.7 million for the quarter. The data is comprehensive and supports the company’s claims of steady operational and financial progress.

Analysis

The announcement is a factual quarterly and year-to-date financial results release, with all key claims directly supported by disclosed GAAP and non-GAAP figures. There are no forward-looking statements or projections; all claims are realised and relate to the reporting periods ended October 3, 2026. The company provides comprehensive data on revenue, gross profit, net income, EPS, adjusted EBITDA, segment performance, margins, and balance sheet items. Growth is modest but consistent across all major metrics, and the tone is proportionate to the results. There is no evidence of narrative inflation, exaggerated language, or claims of future benefits not yet realised. No large capital outlay or deferred benefit is disclosed.

Risk flags

• ●RCM Technologies’ cash balance is low at $1.9 million as of October 3, 2026, which could constrain flexibility if working capital needs rise or if there are unexpected disruptions. This is notable given the company’s size and revenue base.
• ●Net cash used in operating activities was $3.7 million for the quarter and $6.3 million year-to-date, indicating that despite profitability, the business is not currently generating positive operating cash flow. Sustained negative cash flow could pressure liquidity if not reversed.
• ●Accounts receivable and contract assets stand at $85.0 million, a significant portion of total assets ($133.2 million). High receivables relative to cash and equity may expose the company to collection risk or working capital strain if customer payments are delayed.

Bottom line

RCM Technologies delivered another quarter and year-to-date period of incremental revenue and profit growth, with non-GAAP metrics showing especially strong improvement. The company’s operational performance is supported by detailed segment and margin disclosures, and the narrative is well-aligned with the underlying numbers. However, the low cash balance and continued negative operating cash flow warrant attention, as they could limit the company’s ability to weather shocks or invest in growth. Receivables are high relative to cash and equity, adding another layer of financial risk. Investors should focus on whether RCM can convert accounting profits into sustainable operating cash flow in future quarters. The most important takeaway is that while headline growth is real, underlying liquidity and cash generation remain key areas to monitor.

Announcement summary

(NASDAQ:RCMT) RCM Technologies, Inc. announced financial results for the thirteen and thirty-nine weeks ended October 3, 2026. Revenue for the thirteen weeks ended October 3, 2026 was $73.4 million, up 4.4% from $70.3 million in the prior-year quarter. Gross profit for the current quarter was $19.9 million, a 2.7% increase from $19.4 million in the comparable prior quarter. GAAP net income for the current quarter was $2.7 million, or $0.37 per diluted share, compared to $2.3 million, or $0.30 per diluted share, in the prior-year quarter. Adjusted EBITDA (non-GAAP) for the current quarter was $6.3 million, up from $5.5 million in the comparable prior quarter, representing a 14.2% increase. Adjusted net income per diluted share (non-GAAP) for the current quarter was $0.53, compared to $0.42 in the prior-year quarter, an increase of 26.2%. For the thirty-nine weeks ended October 3, 2026, revenue was $250.3 million, a 7.4% increase from $232.9 million in the comparable prior-year period. Gross profit for the current period was $66.0 million, up 3.7% from $63.7 million in the prior-year period. GAAP net income for the current period was $11.5 million, or $1.56 per diluted share, compared to $10.2 million, or $1.34 per diluted share, in the prior-year period. Adjusted EBITDA (non-GAAP) for the current period was $23.8 million, up from $21.4 million in the prior-year period, an 11.0% increase. Adjusted net income per diluted share (non-GAAP) for the current period was $2.01, compared to $1.73 in the prior-year period, an increase of 16.2%. Segment revenue for the thirteen weeks ended October 3, 2026 was $33.7 million for Specialty Healthcare, $30.7 million for Engineering, and $8.9 million for Life Sciences, Data and Solutions. Gross profit margins for the current quarter were 25.5% for Specialty Healthcare, 25.9% for Engineering, and 37.7% for Life Sciences, Data and Solutions, with a consolidated margin of 27.1%. For the thirty-nine weeks ended October 3, 2026, segment revenue was $126.5 million for Specialty Healthcare, $96.4 million for Engineering, and $27.3 million for Life Sciences, Data and Solutions. Gross profit margins for the current period were 27.8% for Specialty Healthcare, 21.1% for Engineering, and 38.6% for Life Sciences, Data and Solutions, with a consolidated margin of 26.4%. As of October 3, 2026, cash was $1.9 million, accounts receivable and contract assets were $85.0 million, and total assets were $133.2 million. Total current liabilities as of October 3, 2026 were $47.9 million, and total liabilities were $80.2 million. Stockholders’ equity as of October 3, 2026 was $53.0 million. Net cash used in operating activities for the thirteen weeks ended October 3, 2026 was $3.7 million, and for the thirty-nine weeks ended October 3, 2026 was $6.3 million. The company used an estimated effective income tax rate of 27.0% for both periods presented.

Disagree with this article?